Showing results (401-410 of 887) with videos related to

Sort By:
Pageof 89
European Heart Journal|March 23, 2013
Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry diseaseJohannes Krämer, Markus Niemann, Dan Liu, et al.
European Journal of Preventive Cardiology|May 16, 2017
Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: Insights from the EUROASPIRE IV survey of the European Society of CardiologyMartin Wagner, Christoph Wanner, Kornelia Kotseva, et al.
European Journal of Heart Failure|December 15, 2010
Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase AWolfram Machann, Frank Breunig, Frank Weidemann, et al.
Plos One|May 30, 2015
Effect of High-Flux Dialysis on Circulating FGF-23 Levels in End-Stage Renal Disease Patients: Results from a Randomized TrialAndreas Schneider, Markus P Schneider, Detlef H Krieter, et al.
Clinical Pharmacology and Therapeutics|July 13, 2017
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme ReplacementNicolas Guérard, Daniel Oder, Peter Nordbeck, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 18, 2023
Guardians For Health: A Practical Approach to Improving Quality of Life and Longevity in People with Type 2 DiabetesNaresh Kanumilli, Javed Butler, Konstantinos Makrilakis, et al.
Kidney International. Supplement|April 16, 2003
Fabry disease: diagnosis and treatmentFrank Breunig, Frank Weidemann, Meinrad Beer, et al.
BMJ Open Diabetes Research & Care|July 5, 2022
Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuriaJanet B McGill, Hermann Haller, Prabir Roy-Chaudhury, et al.
CJC Open|July 19, 2024
Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME TrialAyodele Odutayo, Bernard Zinman, Christoph Wanner, et al.
Kidney International|July 5, 2024
Clinical trial designs to assess treatment effects on glomerular filtration rate declineHiddo J L Heerspink, Dustin J Little, Lars Frison, et al.
Pageof 89